4 results match your criteria: "HIV-1 Associated Acute Chronic Inflammatory Demyelinating Polyneuropathy"
J Family Med Prim Care
May 2019
Department of Medicine, RPGMC Tanda, Kangra, Himachal Pradesh, India.
Rev Neurol
April 2004
Neurología, Policlínico Docente, La Habana, Cuba.
J Peripher Nerv Syst
March 2001
Department of Neurology, University of Miami School of Medicine and Jackson Memorial Hospital, Florida, USA.
MMWR Morb Mortal Wkly Rep
June 1999
Immune globulin intravenous (IGIV) is a sterile, highly purified immunoglobulin G (IgG) preparation made from pooled human plasma stabilized with glucose, maltose, glycine, sucrose, sorbitol, or albumin and is used as prophylaxis or therapy for various medical disorders. The Food and Drug Administration (FDA) first licensed IGIV in 1981 and has approved its use for six conditions: primary immunodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, recent bone marrow transplantation in patients aged > or =20 years, chronic B-cell lymphocytic leukemia, and pediatric human immunodeficiency virus type 1 (HIV-1) infection. In clinical practice, IGIV has been known to be used to treat 50-60 unapproved conditions, including acute lymphoblastic leukemia, adult HIV infection, multiple sclerosis, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy.
View Article and Find Full Text PDF